28 assets in Anal Squamous Cell Carcinoma

Therapeutic assets addressing Anal Squamous Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Fluorouracilum Anal Squamous Cell Carcinoma	Columbia University	P2	BB (66)
Carboplatin Anal Squamous Cell Carcinoma	Fudan University	P3	BB (64)
Cis-Diamminedichloroplatinum Ii Anal Squamous Cell Carcinoma	Sixth Affiliated Hospital, Sun Yat-sen University	P3	BB (64)
Nivolumab Anal Squamous Cell Carcinoma	National Cancer Institute (NCI)	P3	BB (64)
Atezolizumab Anal Squamous Cell Carcinoma	Oncolytics Biotech	P2	B (60)
e7 tcr-t cells Anal Squamous Cell Carcinoma	Christian Hinrichs	P2	B (58)
Toripalimab Anal Squamous Cell Carcinoma	Sun Yat-sen University	P2	B (57)
Capecitabine Anal Squamous Cell Carcinoma	Columbia University	P2	CCC (53)
Fludeoxyglucose Anal Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Muamycin Anal Squamous Cell Carcinoma	Columbia University	P2	CCC (53)
Regorafenib Anal Squamous Cell Carcinoma	Translational Research in Oncology	P2	CCC (53)
Retifanlimab Anal Squamous Cell Carcinoma	Jennifer Dorth	P2	CCC (53)
Tislelizumab Anal Squamous Cell Carcinoma	Translational Research in Oncology	P2	CCC (53)
Cyclophosphamide Anal Squamous Cell Carcinoma	SCG Cell Therapy Pte. Ltd.	P1/2	CCC (52)
Fludarabine Anal Squamous Cell Carcinoma	SCG Cell Therapy Pte. Ltd.	P1/2	CCC (52)
Bmx-001 Free Base Anal Squamous Cell Carcinoma	University of Nebraska	P1/2	CCC (48)
Idp-001 Anal Squamous Cell Carcinoma	InduPro, Inc.	P1/2	CCC (48)
Pelareorep Anal Squamous Cell Carcinoma	Oncolytics Biotech	P1/2	CCC (48)
Trifluridine/Tipiracil Hydrochloride Combination Agent Tas-102 Anal Squamous Cell Carcinoma	Oncolytics Biotech	P1/2	CCC (48)
scg142 Anal Squamous Cell Carcinoma	SCG Cell Therapy Pte. Ltd.	P1/2	CC (45)
Evolve104 Anal Squamous Cell Carcinoma	EvolveImmune United, Inc	P1	CC (43)
Tsc-200-A0201 Anal Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-201-B0702 Anal Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-202-A0201 Anal Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-203-A0201 Anal Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-204-A0101 Anal Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-204-A0201 Anal Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)
Tsc-204-C0702 Anal Squamous Cell Carcinoma	TScan Therapeutics, Inc.	P1	CC (41)